Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Acquisitions & Divestments (2018 - 2025)

Historic Change in Acquisitions & Divestments for UroGen Pharma (URGN) over the last 8 years, with Q3 2025 value amounting to $40.2 million.

  • UroGen Pharma's Change in Acquisitions & Divestments rose 23118.62% to $40.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $180.9 million, marking a year-over-year increase of 33837.43%. This contributed to the annual value of $107.7 million for FY2024, which is 11947.91% up from last year.
  • Per UroGen Pharma's latest filing, its Change in Acquisitions & Divestments stood at $40.2 million for Q3 2025, which was up 23118.62% from $30.3 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Change in Acquisitions & Divestments peaked at $70.0 million during Q4 2024, and registered a low of -$88000.0 during Q2 2022.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $13.6 million (2022), whereas its average is $20.3 million.
  • In the last 5 years, UroGen Pharma's Change in Acquisitions & Divestments crashed by 10080.12% in 2022 and then surged by 434431.82% in 2023.
  • Over the past 5 years, UroGen Pharma's Change in Acquisitions & Divestments (Quarter) stood at $9.6 million in 2021, then surged by 140.07% to $23.1 million in 2022, then tumbled by 84.71% to $3.5 million in 2023, then soared by 1879.21% to $70.0 million in 2024, then plummeted by 42.53% to $40.2 million in 2025.
  • Its last three reported values are $40.2 million in Q3 2025, $30.3 million for Q2 2025, and $40.4 million during Q1 2025.